< Back to previous page
Researcher
Michel Delforge
- Disciplines:Laboratory medicine, Palliative care and end-of-life care, Regenerative medicine, Other basic sciences, Other health sciences, Nursing, Other paramedical sciences, Other translational sciences, Other medical and health sciences
Affiliations
- Laboratory of Experimental Hematology (Division)
Member
From1 Jan 2021 → Today - Stem Cell and Developmental Biology (Division)
Member
From1 Apr 2013 → 31 Dec 2020 - Faculty of Medicine (Faculty)
Member
From1 Oct 2000 → 30 Sep 2002
Projects
1 - 10 of 19
- Ultra-sensitive minimal residual disease assessment by blood-based clonotypic mass spectrometry approach in plasma cell dyscrasias (MASSIAS)From1 Jan 2024 → TodayFunding: Own budget, for example: patrimony, inscription fees, gifts
- Optimizing the use of bispecific antibody treatment in Multiple Myeloma by studying the immune microenvironment and cellular mechanisms of drug resistance.From1 Oct 2023 → TodayFunding: FWO Strategic Basic Research Grant
- Ultra-sensitive minimal residual disease assessment by blood-based clonotypic mass spectrometry approach in plasma cell dyscrasias (MASSIAS)From1 Oct 2023 → TodayFunding: FWO Applied Biomedical Research (TBM)
- Development, Validation, and Valorization of a Patient Preference Platform to Inform Healthcare Decision-MakingFrom1 Mar 2023 → TodayFunding: IOF - technology validation in lab
- Positron emission tomography combined with innovative laboratory techniques for improved risk and disease assessment in myeloma.From1 Jan 2021 → TodayFunding: FWO Applied Biomedical Research (TBM)
- Risk prediction and modeling of cancer therapy related cardiotoxicityFrom1 Oct 2020 → TodayFunding: Own budget, for example: patrimony, inscription fees, gifts
- Atomic Force Microscopy Enhanced Spectroscopy to Study Strains and Seeding of Amyloids In SituFrom1 May 2020 → TodayFunding: FWO Medium Size Research Infrastructure
- Augmenting THherapeutic Effectiveness through Novel AnalyticsFrom1 Apr 2020 → 31 Dec 2023Funding: VLAIO - Personalised Medicine ICON
- Het KU Leuven Kankerinstituut (LKI): interdisciplinaire samenwerking ter bevordering van kankeronderzoek, kankerbehandeling en –zorg.From1 Jan 2020 → TodayFunding: BOF - research organisations
- Unravelling the mechanisms of drug resistance to proteasome inhibitors to optimize treatment in patients with multiple myeloma.From1 Jul 2019 → 30 Jun 2023Funding: Foundations, funds and other with scientific goal
Publications
21 - 30 of 265
- Phase I Study of Safety and Pharmacokinetics of RO7297089, an Anti-BCMA/CD16a Bispecific Antibody, in Patients with Relapsed, Refractory Multiple Myeloma.(2023)
Authors: Michel Delforge
Pages: 43 - 51 - Ciltacabtagene Autoleucel for Patients With Triple-class Exposed Multiple Myeloma: Adjusted Comparison of CARTITUDE-1 Patient Outcomes Versus Real-world Clinical Practice(2022)
Authors: Michel Delforge
- What matters most to patients with multiple myeloma? A Pan-European patient preference study(2022)
Authors: Rosanne Janssens, Elise Schoefs, Michel Delforge, Martina Vandebroek, Steven Simoens, Isabelle Huys
- MM-183 CARTITUDE-2 Cohort A: Updated Clinical Data and Biological Correlative Analyses of Ciltacabtagene Autoleucel (cilta-cel) in Lenalidomide-Refractory Patients With Progressive Multiple Myeloma (MM) After 1-3 Prior Lines of Therapy (LOT).(2022)
Authors: Michel Delforge
Pages: S411 - Multiple myeloma: EHA-ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up (vol 33, pg 117, 2022)(2022)
Authors: Michel Delforge
Pages: 988 - 988 - Patient experience before and after treatment with idecabtagene vicleucel (ide-cel, bb2121): qualitative analysis of patient interviews in the KarMMa trial(2022)
Authors: Michel Delforge
- Treatment emergent peripheral neuropathy in the CASSIOPEIA trial(2022)
Authors: Michel Delforge
Pages: 1726 - 1730 - Teclistamab in Relapsed or Refractory Multiple Myeloma(2022)
Authors: Michel Delforge
Pages: 495 - 505 - Matching-adjusted indirect comparison (MAIC) of teclistamab (tec) versus selinexordexamethasone (sel-dex) for the treatment of patients (pts) with triple-class exposed (TCE) relapsed/refractory multiple myeloma (RRMM).(2022)
Authors: Michel Delforge
- LocoMMotion: a prospective, non-interventional, multinational study of real-life current standards of care in patients with relapsed and/or refractory multiple myeloma(2022)
Authors: Michel Delforge
Pages: 1371 - 1376
Patents
1 - 2 of 2
- Cell therapy for myelodysplastic syndromes (Inventor)
- CELL THERAPY FOR MYELODYSPLASTIC SYNDROMES (Inventor)